WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 5801 Infant (under 12 months) mortality rate: 572
GDP / capita (US$): 1'1861 Child (under 5 years) mortality rate: 792

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 28'829  28'011  27'212  26'434  25'677  18'068  13'248  11'848 
Births 1'125  1'105  1'085  1'065  1'046  818  625  557 
Surviving infants 1'052  1'032  1'013  993  974  733  536  474 
Pop. less than 5 years 4'950  4'844  4'743  4'644  4'545  3'290  2'392  2'139 
Pop. less than 15 years 12'979  12'661  12'353  12'039  11'721  8'129  6'254  5'239 
Female 15-49 years 6'767  6'559  6'354  6'160  5'977  4'339  3'024  2'769 

Number of reported cases

(Click for retrospective incidence data for Mozambique)
Diphtheria
ChartChart
  11 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  79  145  7'375  18'082  30'070 
Mumps
ChartChart
 
Pertussis
ChartChart
  94  451 
Polio*
ChartChart
  65 
Rubella
ChartChart
  210  127  428 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  271  59  42  34  101 
Tetanus (total)**
ChartChart
  281  59  110  65  102  573 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Mozambique)
Vaccine year result method % card seen                                                
BCG 2010  91  DHS   83  99*  95  94  93  91  99*  59 
DTP1 2010  91  DHS   83  99*  90  93  93  91  99* 
DTP3 2010  76  DHS   83  96  80  88  78  76  88  46 
DTP4         
IPV1          84  93 
HepB_BD         
HepB3          96  80  88  78  76 
Hib3          96  80  88  78  76 
JapEnc         
MCV1          91  85  87  85  82  97  59 
MCV2          51 
MenA         
PCV1          99*  90  91  80 
PCV2          95  85  89  70 
PCV3          95  80  88  60 
Pol3 2010  73  DHS   83  91  80  88  78  73  87  46 
Rota1          88  99* 
RotaC          76  59 
RCV1         
TT2plus 2010  56  DHS   83  92  80  66  64  70  61  21 
PAB         
VAD1          66  59 
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Mozambique)
BCG
ChartChart
  95  95  94  93  91  84  59 
DTP1
ChartChart
  90  90  92  93  91  84  71 
DTP3
ChartChart
  80  80  79  78  76  70  46 
HepB3
ChartChart
  80  80  79  78  76 
HepB_BD
 
Hib3
ChartChart
  80  80  79  78  76 
IPV1
  84 
MCV1
ChartChart
  91  85  85  85  82  71  59 
MCV2
ChartChart
  51 
PCV3
ChartChart
  80  80  73  45 
Pol3
ChartChart
  80  80  79  78  73  69  46 
RCV1
 
RotaC
ChartChart
  76  17 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 159  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHibHepB 6, 10, 14 weeks; Yes
IPV 14 weeks; Yes
Measles 9, 18 months; Yes
MR 9, 18 months; From November 2017
OPV 6, 10, 14 weeks; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
TT 1st contact; +1, +6 months; +1, +1 year; Yes
VitaminA 6, 12, 18, 24, 30, 36 months;

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2015-2019  2014-2018  2014-2018  2012-2016  2012-2016  2009-2013 
Nº of districts with microplans that include activities to raise immunization coverage number   148  148  148  148  144  66 

System performance

Total Nº districts in country number 159  148  148  148  148  144  144 
Nº districts with DTP3 coverage >=80% number   127  130  128  136  98  43 
% of districts with DTP3 coverage >=80% From 0 to 100%   86  88  86  92  68  30 
Nº districts with measles (MCV1) coverage >=95% number   55  67  44  63  42  70 
% of districts with MCV1 coverage >=95% From 0 to 100%   37  45  30  43  29  49 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   No  Yes  No  No  No  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   No  Yes  No  No  No  No 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   20    23  34  24  25 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.